DHA and AA in Neuronal Development and Function: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Catherine Yang and Version 1 by Rodrigo Valenzuela.

The role of docosahexaenoic acid (DHA) and arachidonic acid (AA) in neurogenesis and brain development throughout the life cycle is fundamental. DHA and AA are long-chain polyunsaturated fatty acids (LCPUFA) vital for many human physiological processes, such as signaling pathways, gene expression, structure and function of membranes, among others. DHA and AA can modulate neuronal function by influencing: (i) the physical properties of neuronal membranes by modulating ion channels and vesicular transport for endo/exocytosis of membrane-bound proteins; (ii) signal transduction, by modulating G protein-mediated second messenger systems; and (iii) gene expression, through direct binding to transcription factors or through the regulation of signaling cascades by eicosanoids derived from AA and DHA-derived docosanoids. In this sense, DHA and AA are crucial for the metabolism, growth, and differentiation of neurons.

  • docosahexaenoic acid
  • arachidonic acid
  • neuroprotection
  • neurodegeneration

1. DHA in Neuronal Metabolism

DHA represents more than 90% of the n-3 LCPUFA in the brain [31][1], mainly as part of the membrane phospholipids in the brain gray matter [6[2][3],96], constituting 35% of the total fatty acids in the synaptic membranes [97][4]. DHA is primarily esterified to phosphatidylethanolamine, phosphatidylserine, and to a lesser extent phosphatidylcholine in neuronal membranes. The structural properties of DHA, such as the length of its carbon chain and its six double bonds, give flexibility and fluidity to the neuronal plasma membrane, facilitating signal transduction into the cell [10,11][5][6]. The fluidity of the neuronal membrane facilitates the lateral movement of receptors, G proteins, ion channels [98][7], enzymes [99][8], and neuroreceptors, increasing the efficiency in signal transduction [100,101,102][9][10][11]. In the brain, DHA is involved in neuronal growth, neuronal migration, synaptogenesis, synaptic plasticity, and gene expression [11,12,13,103][6][12][13][14]. Neurons cannot form DHA from its precursor ALA, but the glial cells, (especially astrocytes) can desaturate and elongate dietary ALA to convert it into DHA, which is subsequently transferred to most neurons [104,105][15][16]. DHA can also modulate the expression of genes related to neuronal energy generation involved in the function of the respiratory chain and ATP synthesis (adenosine triphosphate synthase) [103,104,105][14][15][16]. That function is relevant because approximately 50% of mitochondrial ATP is consumed by the Na+/K+ ATPase pump to maintain cell homeostasis and ionic gradients, a fundamental requirement for neuronal electrical excitability [103,104,105][14][15][16].

2. AA in Neuronal Metabolism

AA is one of the most abundant fatty acids in the brain [26][17]. This n-6 LCPUFA is indispensable for brain growth and modulation of cell division and signaling [29][18]. During brain development, the concentration of AA increases rapidly [106][19]. It has been described in animal models that approximately 70–80% of AA concentration that is reached in adulthood is the result of its cerebral accumulation in the early postnatal period [2][20]. AA is an immediate precursor of adrenic acid (C22:4n-6, AdA), fatty acid found in large amounts in myelinic lipids, especially in phosphatidylethanolamine and phosphatidylcholine [106[19][21],107], suggesting the fundamental role of AA as a precursor of AdA in the development of neural tissue [106][19]. Conversion of AA to AdA may represent an important mechanism for supplying the high demand for AdA at the brain level, which is essential for neuronal myelinic lipid enrichment [2,106][19][20]. Wijendran et al. (2002) [108][22] investigated the metabolism of preformed AA in newborn baboons by the administration of a single oral dose of C13-labeled AA, reporting that 79–93% of AA consumed accumulates in brain membrane lipids and approximately 5% to 16% of AA is transformed into AdA [108][22]. Brain accumulation of AA and AdA occurs during the first month of life and represent 17% and 8% of the total n-6 LCPUFA, respectively [108][22].
Another brain function of AA is directly related to its participation in phosphatidylcholine (PC) structure [107][21]. Some intracellular phospholipid bilayers include AA-containing PC (AA-PC), a structure that plays a role as second messenger participating in the long-term enhancement of synapses in the CA1 region of the hippocampus [109][23]. Using image mass spectrometry, Yang et al. (2012) [110][24] characterized the distribution of AA-PC within neurons in cultured upper cervical nodes, finding an increasing gradient of AA-PC along the proximal to distal axonal axis suggesting that this structure is an important source of free AA [110][24]. Furthermore, it has been described that free AA can activate protein kinases and ion channels and inhibit neurotransmitter recycling [29][18], thus contributing to better control of synaptic transmission [70][25]. In addition to the role of AA in modulating neuronal excitability, AA is also essential in neuronal development in part because it is directly responsible for the activation of syntaxin-3, a protein of the neuronal membrane involved in the growth and neurite repair, an essential process in neurogenesis and subsequently in synaptic transmission [111][26].

3. DHA and AA as Precursors of Endocannabinoids

Remarkably, LCPUFA levels in the brain are highly correlated with dietary intake of PUFA and LCPUFA [112][27]. DHA and AA are precursors of many bioactive lipid mediators identified as docosanoids and eicosanoids, respectively, which are actively involved in regulatory responses in inflammation (eicosanoids such as prostaglandins, prostacyclins, thromboxanes, leucotrienes) and in resolution of inflammation (docosanoids such as resolvins and maresins) [113][28]. Both LCPUFA are also involved in the formation of endocannabinoids (eCB) with regulatory effects at the central nervous system (CNS) [114][29]. The endocannabinoid system consists of eCB, eCB receptors CB1 and CB2, and associated anabolic and catabolic enzymes [115][30]. Their functions are to maintain body energy homeostasis through the nutrient availability detection and the modulation of orexinergic inputs in selective regions of the CNS [116][31]. PUFA derived eicosanoids and eCB have been identified as independent ligands of CB1 and CB2 receptors [115][30]. Hammels et al. (2019) [115][30] reported that CB1 ligands synthesis in CNS depends on dietary intake of AA and DHA in a model of fatty acid desaturase 2-deficient mouse [115][30]. Moreover, DHA and AA have been recognized as ligands of the nuclear RxR receptor in the brain, being the PUFA ratio in the western diet, a critical nutritional parameter for numerous neurodegenerative diseases [115][30], which could increase neuroinflammation and over-stimulation of the endocannabinoid system [117][32]. AA bound to phospholipids determines the formation of eCB, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), molecules involved in the regulation of neuroinflammatory responses by microglia and astrocytes [114][29]. On the contrary, long-term supplementation with DHA and EPA reduces AEA and 2-AG synthesis [118][33]. N-3 and n-6 PUFA derived eCB are synthesized by lipoxygenases (LOX), cyclooxygenase 2 (COX-2), and cytochrome P450 epoxygenases (CYP450). Nevertheless, only LOX and CYP450 metabolites have been reported for a DHA eCB derivative; n-docosahexaenoylethanolamide (DHEA), and only CYP450 metabolites for an EPA eCB derivative; eicosapentaenoyl ethanolamide (EPEA) [116][31]. The physiological role of the metabolites generated by LOX and CYP450 remains to be elucidated to understand how these derivatives modulate cell signaling in health and disease [116][31]. A better understanding of the relationship between DHA, AA, and the endocannabinoid system is expected to lead to advances in the development of their therapeutic potential and the development of more specific treatment options for the prevention and treatment of neurodegenerative diseases [114][29].

References

  1. O’Brien, J.S.; Sampson, E.L. Fatty acid and fatty aldehyde composition of the major brain lipids in normal human gray matter, white matter, and myelin. J. Lipid Res. 1965, 6, 545–551.
  2. Weiser, M.J.; Butt, C.M.; Mohajeri, M.H. Docosahexaenoic Acid and Cognition throughout the Lifespan. Nutrinets 2016, 8, 99.
  3. Giusto, N.M.; Salvador, G.A.; Castagnet, P.I.; Pasquaré, S.J.; Ilincheta de Boschero, M.G. Age-associated changes in central nervous system glycerolipid composition and metabolism. Neurochem. Res. 2002, 27, 1513–1523.
  4. Innis, S.M. Biology of metabolism in growing animals. In Essential Fatty Acid Metabolism During Early Development; Burrin, D.G., Ed.; Elsevier Science: Amsterdam, The Netherlands, 2005; pp. 235–274.
  5. Gawrisch, K.; Eldho, N.V.; Holte, L.L. The structure of DHA in phospholipid membranes. Lipids 2003, 38, 445–452.
  6. Valenzuela, R.; Morales, J.; Sanhueza, J.; Valenzuela, A. Docosahexaenoic acid (DHA), an essential fatty acid at the brain. Rev. Chil. Nutr. 2013, 40, 383–390.
  7. Poling, J.S.; Karanian, J.W.; Salem, N.; Vicini, S. Time- and voltage-dependent block of delayed rectifier potassium channels by docosahexaenoic acid. Mol. Pharmacol. 1995, 47, 381–390.
  8. Strokin, M.; Chechneva, O.; Reymann, K.G.; Reiser, G. Neuroprotection of rat hippocampal slices exposed to oxygen-glucose dep-rivation by enrichment with docosahexaenoic acid and by inhibition of hydrolysis of docosahexaenoic acid-containing phos-pholipids by calcium independent phospholipase A2. Neuroscience 2006, 140, 547–553.
  9. De Lion, S.; Chalon, S.; Guilloteau, D.; Besnard, J.-C.; Durand, G. α-Linolenic Acid Dietary Deficiency Alters Age-Related Changes of Dopaminergic and Serotoninergic Neurotransmission in the Rat Frontal Cortex. J. Neurochem. 2002, 66, 1582–1591.
  10. Cheng, L.; Hu, T.; Shi, H.; Chen, X.; Wang, H.; Zheng, K.; Huang, X.-F.; Yu, Y. DHA reduces hypothalamic inflammation and improves central leptin signaling in mice. Life Sci. 2020, 257, 118036.
  11. Chalon, S.; Delion-Vancassel, S.; Belzung, C.; Guilloteau, D.; Leguisquet, A.M.; Besnard, J.C.; Durand, G. Dietary fish oil affects mon-oaminergic neurotransmission and behavior in rats. J. Nutr. 1998, 128, 2512–2519.
  12. Katakura, M.; Hashimoto, M.; Shahdat, H.; Gamoh, S.; Okui, T.; Matsuzaki, K.; Shido, O. Docosahexaenoic acid promotes neuronal differentiation by regulating basic helix–loop–helix transcription factors and cell cycle in neural stem cells. Neuroscience 2009, 160, 651–660.
  13. Jumpsen, J.; Lien, E.L.; Goh, Y.K.; Clandinin, M.T. Small changes of dietary (n-6) and (n-3)/fatty acid content ration alter phosphatidylethanolamine and phosphatidylcholine fatty acid composition during development of neuronal and glial cells in rats. J. Nutr. 1997, 127, 724–731.
  14. Feltham, B.A.; Louis, X.L.; Eskin, A.M.N.; Suh, M. Docosahexaenoic Acid: Outlining the Therapeutic Nutrient Potential to Combat the Prenatal Alcohol-Induced Insults on Brain Development. Adv. Nutr. 2020, 11, 724–735.
  15. Singh, R.B.; Gupta, S.; Dherange, P.; de Meester, F.; Wilczynska, A.; Alam, S.E.; Pella, D.; Wilson, D.W. Metabolic syndrome: A brain disease. Can. J. Physiol. Pharmacol. 2012, 90, 1171–1183.
  16. Masliah, E.; Crews, L.; Hansen, L. Synaptic remodeling during aging and in Alzheimer’s disease. J. Alzheimers Dis. 2006, 9, 91–99.
  17. Hadley, K.B.; Ryan, A.S.; Forsyth, S.; Gautier, S.; Salem, N. The Essentiality of Arachidonic Acid in Infant Development. Nutrients 2016, 8, 216.
  18. Harauma, A.; Hatanaka, E.; Yasuda, H.; Nakamura, M.T.; Salem, N.; Moriguchi, T. Effects of arachidonic acid, eicosapentaenoic acid and docosahexaenoic acid on brain development using artificial rearing of delta-6-desaturase knockout mice. Prostaglandins Leukot. Essent. Fat. Acids 2017, 127, 32–39.
  19. Martinez, M. Tissue levels of polyunsaturated fatty acids during early human development. J. Pediatr. 1992, 120, S129–S138.
  20. Crawford, M.A.; Broadhurst, C.L. The role of docosahexaenoic and the marine food web as determinants of evolution and hominid brain development: The challenge for human sustainability. Nutr. Health 2012, 21, 17–39.
  21. Hsieh, A.T.; Anthony, J.C.; Diersen-Schade, D.A.; Rumsey, S.C.; Lawrence, P.; Li, C.; Nathanielsz, P.W.; Brenna, J.T. The Influence of Moderate and High Dietary Long Chain Polyunsaturated Fatty Acids (LCPUFA) on Baboon Neonate Tissue Fatty Acids. Pediatr. Res. 2007, 61, 537–545.
  22. Wijendran, V.; Lawrence, P.; Diau, G.-Y.; Boehm, G.; Nathanielsz, P.; Brenna, J. Significant utilization of dietary arachidonic acid is for brain adrenic acid in baboon neonates. J. Lipid Res. 2002, 43, 762–767.
  23. Alashmali, S.M.; Kitson, A.P.; Lin, L.; Lacombe, R.J.S.; Bazinet, R.P. Maternal dietary n-6 polyunsaturated fatty acid deprivation does not exacerbate post-weaning reductions in arachidonic acid and its mediators in the mouse hippocampus. Nutr. Neurosci. 2017, 22, 223–234.
  24. Yang, H.-J.; Sugiura, Y.; Ikegami, K.; Konishi, Y.; Setou, M. Axonal Gradient of Arachidonic Acid-containing Phosphatidylcholine and Its Dependence on Actin Dynamics. J. Biol. Chem. 2012, 287, 5290–5300.
  25. Lauritzen, L.; Hansen, H.S.; Jørgensen, M.H.; Michaelsen, K.F. The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog. Lipid. Res. 2001, 40, 1–94.
  26. Darios, F.; Davletov, B. Omega-3 and omega-6 fatty acids stimulate cell membrane expansion by acting on syntaxin 3. Nat. Cell Biol. 2006, 440, 813–817.
  27. Novak, E.M.; Dyer, R.A.; Innis, S.M. High dietary omega-6 fatty acids contribute to reduced docosahexaenoic acid in the developing brain and inhibit secondary neurite growth. Brain Res. 2008, 1237, 136–145.
  28. Buckley, C.D.; Gilroy, D.W.; Serhan, C.N. Proresolving lipid mediators and mechanisms in the resolution of acute inflam-mation. Immunity 2014, 40, 315–327.
  29. Dyall, S.C. Interplay between n-3 and n-6 Long-Chain Polyunsaturated Fatty Acids and the Endocannabinoid System in Brain Protection and Repair. Lipids 2017, 52, 885–900.
  30. Hammels, I.; Binczek, E.; Schmidt-Soltau, I.; Jenke, B.; Thomas, A.; Vogel, M.; Thevis, M.; Filipova, D.; Papadopoulos, S.; Stoffel, W. Novel CB1-ligands maintain homeostasis of the endocannabinoid system in ω3- and ω6-long-chain-PUFA deficiency. J. Lipid Res. 2019, 60, 1396–1409.
  31. Watson, J.E.; Kim, J.S.; Das, A. Emerging class of omega-3 fatty acid endocannabinoids & their derivatives. Prostaglandins Other Lipid Mediat. 2019, 143, 106337.
  32. Simopoulos, A. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed. Pharmacother. 2002, 56, 365–379.
  33. Wood, J.T.; Williams, J.S.; Pandarinathan, L.; Janero, D.R.; Lammi-Keefe, C.J.; Makriyannis, A. Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma. J. Lipid Res. 2010, 51, 1416–1423.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback